Drug intelligence / Profile preview

SRN-901

Development stage: Preclinical
Lead developer: Seragon Biosciences
Modality: Small Molecules
Administration: Oral

Overview

SRN-901 is a novel oral combinatorial longevity drug developed by Seragon Biosciences. It is designed to simultaneously modulate interconnected nutrient-sensing, mitochondrial surveillance, and stress-response networks, including AMPK, FoxO, and mTORC1 signaling pathways, as well as glutathione metabolism and DNA repair. The drug is a multi-target intervention composed of urolithin A, quercetin, nicotinamide riboside, alpha-lipoic acid, and a proprietary compound SRN-820. Preclinical studies in aged mice have demonstrated a 33% increase in median remaining lifespan, a 70% attenuation of frailty progression, and a 30.53% reduction in tumor incidence.

Other names: SRN-901SRN901SRN 901

Targets

FOXO1 (Forkhead box protein O1)AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on SRN-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRN-901.

Explore the full profile